Abstract
The recently described complication of late and very late stent thrombosis with coronary stents has raised the question of when is it safe to stop antiplatelet therapy in the era of drug eluting stents? With several million patients having already had coronary stents implanted worldwide, the importance of an appreciation of stent thrombosis is not only critical to the cardiologist but also surgeon, physician, dentist and other specialists that perform procedures on patients which require with-holding antiplatelet agents. Currently there is great concern amongst medical professionals on how to manage this group of patients in the absence of clear guidelines. This article reviews the current data on coronary stents, in-stent restenosis and stent thrombosis and role of antiplatelet medication post percutaneous coronary intervention (PCI) to provide a concise and clear algorithm for managing perioperative antiplatelet therapy in patients having undergone recent PCI. The algorithm encourages a multidisciplinary approach and is based on the surgical bleeding risk, operative risk of adverse cardiac events and stent thrombosis risk to guide safe practice. Challenging areas including aspirin and clopidogrel hypersensitivity, clopidogrel resistance and concomitant vitamin K antagonist therapy are also addressed.
Current Drug Targets
Title: Deciphering Dual Antiplatelet Therapy in the Era of Drug-Eluting Coronary Stents
Volume: 10 Issue: 6
Author(s): Brendan Bell, Darren Walters and Christian Spaulding
Affiliation:
Abstract: The recently described complication of late and very late stent thrombosis with coronary stents has raised the question of when is it safe to stop antiplatelet therapy in the era of drug eluting stents? With several million patients having already had coronary stents implanted worldwide, the importance of an appreciation of stent thrombosis is not only critical to the cardiologist but also surgeon, physician, dentist and other specialists that perform procedures on patients which require with-holding antiplatelet agents. Currently there is great concern amongst medical professionals on how to manage this group of patients in the absence of clear guidelines. This article reviews the current data on coronary stents, in-stent restenosis and stent thrombosis and role of antiplatelet medication post percutaneous coronary intervention (PCI) to provide a concise and clear algorithm for managing perioperative antiplatelet therapy in patients having undergone recent PCI. The algorithm encourages a multidisciplinary approach and is based on the surgical bleeding risk, operative risk of adverse cardiac events and stent thrombosis risk to guide safe practice. Challenging areas including aspirin and clopidogrel hypersensitivity, clopidogrel resistance and concomitant vitamin K antagonist therapy are also addressed.
Export Options
About this article
Cite this article as:
Bell Brendan, Walters Darren and Spaulding Christian, Deciphering Dual Antiplatelet Therapy in the Era of Drug-Eluting Coronary Stents, Current Drug Targets 2009; 10 (6) . https://dx.doi.org/10.2174/138945009788488413
DOI https://dx.doi.org/10.2174/138945009788488413 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial [Hot Topic: Advances in Diagnosing Drug Hypersensitivity Reactions (Executive Editors: A. Romano and M. Ventura)]
Current Pharmaceutical Design Drug Induced Cutaneous Manifestations due to Treatment of Gastrointestinal Disorders
Current Drug Metabolism Acute Hypersensitivity Reactions to Chemotherapy Agents: An Overview
Inflammation & Allergy - Drug Targets (Discontinued) Immunotherapy in Allergies: An Update
Inflammation & Allergy - Drug Targets (Discontinued) Serpin Regulation of Fibrinolytic System: Implications for Therapeutic Applications in Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Extracellular Proteases as Targets for Drug Development
Current Protein & Peptide Science Successful Desensitization of Three Patients with Hypersensitivity Reactions to Omalizumab
Current Drug Safety A Closer Look to Polyesters: Properties, Synthesis, Characterization, and Particle Drug Delivery Applications
Nanoscience & Nanotechnology-Asia The Challenges of Blood Pressure Control in Dialysis Patients
Recent Advances in Cardiovascular Drug Discovery (Discontinued) Chronic Urticaria: An Overview of Treatment and Recent Patents
Recent Patents on Inflammation & Allergy Drug Discovery Peptide and Non-peptide Antagonists Targeting Endothelin Receptors in Physiology and Pathology
Current Pharmaceutical Design Prevalence of Intestinal Parasites among Patients with Chronic Urticaria in Northern Iran
Infectious Disorders - Drug Targets Telmisartan, its Potential Therapeutic Implications in Cardiometabolic Disorders
Recent Patents on Cardiovascular Drug Discovery Role of ARBs in the Blood Hypertension Therapy and Prevention of Cardiovascular Events
Current Drug Targets The Guanylyl Cyclase Inhibition by MB as Vasoplegic Circulatory Shock Therapeutical Target
Current Drug Targets Hypersensitivity Reactions to Anticoagulant Drugs
Current Pharmaceutical Design Serum Sickness Reaction to Rituximab with Positive Immediate Intradermal Skin Test: A Case Report
New Emirates Medical Journal Designed Multiple Ligands: Basic Research vs Clinical Outcomes
Current Medicinal Chemistry Design and Development of Preservative Free Herbal Dosage Forms
The Natural Products Journal Adverse Cutaneous Reactions of Systemic Antihistamines
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents